Progenitor Cells in Airway Repair

气道修复中的祖细胞

基本信息

项目摘要

DESCRIPTION (provided by applicant): Lung transplantation is often the only viable therapeutic option for end-stage pulmonary disorders. Unfortunately, lung transplantation is associated with numerous serious complications including acute rejection and bronchiolitis obliterans syndrome (BOS). Studies have indicated that immune-mediated injury and loss of airway epithelial cells is critical in the pathogenesis of BOS. Targeting this biology could therefore provide a major breakthrough for developing new therapeutic strategies for preventing rejection in lung transplantation. We have identified circulating epithelial progenitor cells (CEPC) that are recruited to the injured airway and aid in repair of the epithelium. These cells express cytokeratin 5, a marker of progenitor basal epithelial cells in the airway, and traffic via the CXCR4/CXCL12 biological axis. Consistent with the importance of CEPC in airway repair, blocking the recruitment of CEPC with neutralizing antibodies to CXCL12 resulted in the phenotype of squamous metaplasia. This implies that the interaction between circulating and resident progenitor epithelial cells in the airway niche is critical for normal airway repair. We hypothesize that enhancing engraftment of recipient CEPC into donor airway epithelium after lung transplantation will improve epithelial repair, result in less allo-recognition of the donor lung and ultimately reduce BOS. The goal of this proposal is to: 1) investigate the role of resident and circulating epithelial progenitor cell populations in the development of BOS by selectively eliminating these cell populations, 2) examine the effect of enhanced mobilization of CEPC on the development of BOS and 3) use patient lung transplant blood samples to determine whether CEPC correlate with patient outcome. The proposed studies will allow further understanding of the role of epithelial progenitor cells in the airway and will enable the harnessing of the therapeutic potential of CEPC. PUBLIC HEALTH RELEVANCE: Adult stem cells hold great promise for repair of the lungs and we have discovered adult stem cells in the blood that contribute to repair of the lungs. Lung transplants are performed for many patients with end stage lung diseases, but are associated with many complications. We hypothesize that mobilizing adult stem cells after lung transplantation will improve the repair of the injured donor lungs and reduce the complications of lung transplantation. We plan to test this hypothesis in preclinical models and in lung transplant patient samples.
描述(由申请人提供):肺移植通常是终末期肺部疾病唯一可行的治疗选择。不幸的是,肺移植与许多严重的并发症有关,包括急性排斥反应和闭塞性细支气管炎综合征(BOS)。研究表明,免疫介导的气道上皮细胞损伤和丢失在BOS的发病机制中至关重要。因此,靶向这种生物学可以为开发新的治疗策略以预防肺移植中的排斥反应提供重大突破。我们已经鉴定出循环上皮祖细胞(CEPC),它们被募集到受损的气道并有助于上皮的修复。这些细胞表达细胞角蛋白5(气道中的祖基底上皮细胞的标志物),并通过CXCR 4/CXCL 12生物轴运输。与CEPC在气道修复中的重要性一致,用CXCL 12的中和抗体阻断CEPC的募集导致鳞状上皮化生的表型。这意味着循环和驻留祖上皮细胞之间的相互作用,在气道生态位是至关重要的正常气道修复。我们假设,肺移植后增强受体CEPC向供体气道上皮的植入将改善上皮修复,导致供体肺的同种异体识别减少,并最终减少BOS。该提案的目的是:1)通过选择性消除驻留和循环上皮祖细胞群来研究这些细胞群在BOS发展中的作用,2)检查CEPC动员增强对BOS发展的影响,3)使用患者肺移植血液样本来确定CEPC是否与患者结局相关。拟议的研究将允许进一步了解上皮祖细胞在气道中的作用,并将能够利用CEPC的治疗潜力。公共卫生相关性:成体干细胞对肺部修复有很大的希望,我们已经发现血液中的成体干细胞有助于肺部修复。肺移植是为许多终末期肺部疾病患者进行的,但与许多并发症相关。我们推测,肺移植后动员成体干细胞将改善受损供体肺的修复,减少肺移植的并发症。我们计划在临床前模型和肺移植患者样本中测试这一假设。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRIGITTE N GOMPERTS其他文献

BRIGITTE N GOMPERTS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRIGITTE N GOMPERTS', 18)}}的其他基金

Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer
制定非小细胞肺癌的靶向化学预防策略
  • 批准号:
    9170948
  • 财政年份:
    2016
  • 资助金额:
    $ 38.5万
  • 项目类别:
Progenitor Cells in Airway Repair
气道修复中的祖细胞
  • 批准号:
    8528692
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Progenitor Cells in Airway Repair
气道修复中的祖细胞
  • 批准号:
    8318148
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Progenitor Cells in Airway Repair
气道修复中的祖细胞
  • 批准号:
    7568010
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Progenitor Cells in Airway Repair
气道修复中的祖细胞
  • 批准号:
    7766243
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Cytokine Regulation of the Pulmonary Epithelium
肺上皮细胞因子的调节
  • 批准号:
    6860476
  • 财政年份:
    2004
  • 资助金额:
    $ 38.5万
  • 项目类别:
Cytokine Regulation of the Pulmonary Epithelium
肺上皮细胞因子的调节
  • 批准号:
    6994423
  • 财政年份:
    2004
  • 资助金额:
    $ 38.5万
  • 项目类别:
Cytokine Regulation of the Pulmonary Epithelium
肺上皮细胞因子的调节
  • 批准号:
    7534033
  • 财政年份:
    2004
  • 资助金额:
    $ 38.5万
  • 项目类别:
Cytokine Regulation of the Pulmonary Epithelium
肺上皮细胞因子的调节
  • 批准号:
    7154784
  • 财政年份:
    2004
  • 资助金额:
    $ 38.5万
  • 项目类别:
Cytokine Regulation of the Pulmonary Epithelium
肺上皮细胞因子的调节
  • 批准号:
    7326813
  • 财政年份:
    2004
  • 资助金额:
    $ 38.5万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 38.5万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 38.5万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 38.5万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 38.5万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 38.5万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 38.5万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 38.5万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 38.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了